Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 25 of the 46 sources its claims cite were checked for support.
Abstract
Heterogeneity in chemotherapeutic response is directly associated with prognosis and disease recurrence in patients with ovarian cancer (OvCa). Despite the significant clinical need, a credible gene signature for predicting response to platinum-based chemotherapy and for guiding the selection of personalized chemotherapy regimens has not yet been identified. The present study used an integrated approach involving both OvCa tumors and cell lines to identify an individualized gene expression signature, denoted as IndividCRS, consisting of 16 robust chemotherapy-responsive genes for predicting intrinsic or acquired chemotherapy response in the meta-discovery dataset. The robust performance of this signature was subsequently validated in 25 independent tumor datasets comprising 2215 patients and one independent cell line dataset, across different technical platforms. The IndividCRS was significantly correlated with the response to platinum therapy and predicted the improved outcome. Moreover, the IndividCRS correlated with homologous recombination deficiency (HRD) and was also capable of discriminating HR-deficient tumors with or without platinum-sensitivity for guiding HRD-targeted clinical trials. Our results reveal the universality and simplicity of the IndividCRS as a promising individualized genomic tool to rapidly monitor response to chemotherapy and predict the outcome of patients with OvCa.
Overview
CoChat Summary
## TL;DR
This study built a 16-gene individualized expression score, IndividCRS, from multiple ovarian cancer tumor and cell-line datasets to predict response to platinum-based chemotherapy. The score was validated across independent datasets and was associated with chemotherapy sensitivity, overall survival, homologous recombination deficiency, and epithelial-mesenchymal transition-related features.
## Key findings
- The final signature contained 16 chemotherapy-responsive genes: 6 chemotherapy-sensitive genes (FZD4, MUTYH, PCK2, PEX10, SRPK1, UCP2) and 10 chemotherapy-resistant genes (EDIL3, GNG12, MBOAT2, MTMR6, NBR1, NEK7, NET1, PPP3CA, RAD17, WDR41).
- In the meta-discovery datasets, patients with high IndividCRS scores (>0) had better outcomes and greater chemotherapy sensitivity; in Patch and TCGA, the score significantly stratified overall survival (Patch, P < 0.001; TCGA, P = 0.002), and the probability of complete response correlated with IndividCRS (r² = 0.88, P < 0.001).
- Validation in independent datasets showed the same direction of effect: sensitive samples had higher IndividCRS than resistant samples in the GDSC cell line dataset (P = 0.041) and in three patient datasets (GSE3149, P = 0.001; GSE51373, P = 0.08; GSE23554, P = 0.011).
- In the TCGA HR-defect analysis (n = 557), HR-defective tumors had significantly higher IndividCRS than HR-intact tumors, and the high-IndividCRS HR-defective group had better overall survival than the HR-intact group (P = 0.02). The overall prognostic meta-analysis across 21 datasets gave HR = 0.67 (95% CI 0.61–0.75, P < 0.001), and multivariable analysis gave HR = 1.54 (95% CI 1.35–1.76, P < 0.001).
## Methods
- Retrospective integrated analysis of public gene-expression and clinical datasets from GEO, TCGA, and the literature: 29 ovarian cancer datasets total, including 3 cell-line datasets and 26 patient datasets, drawn from 12 microarray platforms and 2 RNA-seq platforms.
- Four datasets with response information and larger sample sizes (Dressman, Patch, TCGA, and GSE47856) were used as the meta-discovery set; the remaining 25 datasets were used for independent validation.
- Differential expression was assessed with limma for microarray data and edgeR for RNA-seq data; genes present in at least 3 of the 4 discovery datasets were used to build the 16-gene IndividCRS, and survival/association analyses used Kaplan–Meier, log-rank tests, Wilcoxon tests, t-tests, and meta-analysis.
## Limitations
- The paper states that the signature is “merely a reflective signature of the underlying mechanisms of chemo-response,” and that functional studies are still required.
- The paper also notes that the relationship between IndividCRS and HR deficiency “need be further investigated using functional experiments.”
- Evident from the text: the study is retrospective and based on public datasets, so its findings depend on existing cohort annotation and platform-specific data quality rather than prospective clinical testing.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
19 Valid · 0 Not valid · 6 Not checked · 48 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the majority of OvCa patients that initially respond to chemotherapy treatment develop the recurrent disease due to acquired resistance to platinum-based chemotherapy after undergoing multiple cycles of chemotherapy36.”
§ Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy > Discussion By combining gene expression profiles and chemotherapeutic response information from multiple patients and cell line datasets, the present study developed a gene expression signature comprising 16 chemotherapy-responsive genes, which could predict individual responses to platinum-based chemotherapy for patients with OvCa. Although platinum-based adjuvant chemotherapy is the first-line treatment and is associated with high response rates in OvCa patients, ~30% of patients have been found to develop chemoresistance following multiple cycles of chemotherapy, and ~50% of patients with CR relapse within a few years4,18. Therefore, identifying predictive markers of response to platinum-based chemotherapy is an ongoing focus of research despite continuous efforts have been made during the past number of years. A recent review revealed that the gene signatures identified by previous studies are very dissimilar, and the vast majority of genes were identified using only one study18. In contrast to previous studies, where informative genes were identified based solely on a single dataset and did not take into consideration the heterogeneity of patient cohorts, the present study integrated multiple patient and cell line datasets with chemotherapy treatment to identify the most commonly differentially expressed genes, which were demonstrated as reliable chemotherapy-responsive genes. These chemotherapy-responsive genes include genes involved in the repair of DNA damage (MUTYH, NBR1, NEK7, NET1, and RAD17), and genes previously reported to be associated with the response to chemotherapy (FZD4, SRPK1 and UCP2)30–32. To accelerate the clinical application of our findings, the 16 reliable chemotherapy-responsive genes were integrated to form a gene expression signature (denoted IndividCRS) by comparing expression differences between chemotherapy-sensitive and chemotherapy-resistant genes. Unlike previous linear scoring models, this signature design allowed IndividCRS to have a natural cutoff (IndividCRS = 0) that divided sensitive and resistant tumors. This was associated with statistical significance and eliminated the need for the pre-collection of samples for data normalization and the establishment of trained risk score thresholds. Moreover, the predictive value of the IndividCRS was validated in multiple independent OvCa datasets derived from different laboratories that used different platforms. This demonstrated that the IndividCRS is a robust tool that may allow for the individualized and single-sample prediction of response to platinum-based chemotherapy before initiation of first-line therapy in clinical practice. Increasing evidence suggests that tumors with HR deficiency are more likely to be highly sensitive to platinum-based chemotherapy20–22. Detection of HR deficiency is a widely accepted strategy to identify platinum-sensitive tumors. However, it is worth noting that not all HRD tumors, including BRCA1/2-mutated tumors, are sensitive to platinum agents. Therefore, the relationship between HR deficiency and IndividCRS was examined in the current study, and a potential association between HR deficiency and IndividCRS was identified, indicating that the IndividCRS may be used as an indicator of HR deficiency which need be further investigated using functional experiments. In addition, the IndividCRS can further discriminate between chemoresistance and chemosensitivity in HR-deficient tumors, which may provide valuable information for guiding HRD-targeted clinical trials. Conflicting results have been reported regarding the outcome of OvCa patients harboring BRCA1/2 mutations. A number of studies have demonstrated that not all OvCa patients harboring BRCA1/2 mutations have significantly more favorable outcome than patients with wild-type BRCA, and some patients may even develop platinum resistance33–35. By applying the IndividCRS to BRCA-deficient patients in the present study, a significant difference in OS between BRCA-deficient patients with high IndividCRS and those with low IndividCRS was observed, suggesting that BRCA-deficient patients could be further discriminated by the IndividCRS. Therefore, the IndividCRS may have important clinical applications in identifying BRCA-deficient patients with unfavorable outcomes and allow redirection to more appropriate therapies in time. Despite previous studies claiming that the existing signatures are able to predict survival or response to initial chemotherapy in OvCa patients, the majority of OvCa patients that initially respond to chemotherapy treatment develop the recurrent disease due to acquired resistance to platinum-based chemotherapy after undergoing multiple cycles of chemotherapy36. Therefore, the present study examined the relationship between changes in chemotherapy resistance and the IndividCRS during and after drug treatment. The results demonstrated that the IndividCRS reflected the dynamics of resistance during the treatment. Furthermore, the IndividCRS comprised a minimal number of reliable chemotherapy-responsive genes; the expression of which could be measured using real time-polymerase chain reaction (RT-PCR) in samples obtained by fine needle aspiration. This provides a potential avenue to monitor resistance to platinum-based chemotherapy in real-time for OvCa patients that respond to initial platinum-based chemotherapy in clinical practice, and redirect patients with chemoresistance to more appropriate therapies in time and avoid unnecessary chemotherapy treatment. Accumulating evidence suggests that an interplay exists between EMT and chemotherapeutic response in OvCa. However, previous studies investigating the role of EMT in chemoresistance report inconsistent results24. For instance, the activation of EMT by the EMT-related signaling pathways, such as endothelin A receptor, p53-mediated apoptosis, epidermal growth factor receptor/signal transducer and activator of transcription 3, transforming growth factor-β and Notch3/ERK signaling pathways37–39 or microRNAs, such as microRNA-181a and miR-200 family40,41, have been found to be associated with enhanced resistance to platinum-based chemotherapy. By contrast, several studies have indicated that patients or cell lines with mesenchymal phenotypes demonstrated higher sensitivity to cisplatin when compared with the epithelial phenotype25,42,43. Therefore, the association between EMT and the chemotherapeutic response was investigated in the current study by constructing an EMT score. The results demonstrated that the EMT score, or the key components of EMT, were all negatively correlated with the IndividCRS across multiple datasets. These results provided further evidence to support the association between EMT and platinum-based chemoresistance. In conclusion, the present study used an integrated approach involving both OvCa tumors and cell lines, to identify a number of genes that were differentially expressed between platinum-based chemotherapy-resistant samples and sensitive samples. These genes were then used to construct an individualized scoring model consisting of a 16-gene chemotherapy-responsive panel (IndividCRS) for the prediction of response to platinum-based chemotherapy. The ability of the IndividCRS to predict response to platinum-based chemotherapy and outcome was verified in multiple independent datasets deposited by different laboratories with different platform technologies. The universality and simplicity of the IndividCRS make it a promising individualized predictive tool to monitor patient resistance in a timely manner before and after platinum-based chemotherapy treatment, and can be analyzed using RT-PCR in a clinical setting. However, it is should be noted that the IndividCRS was designed to rely on the consistent upregulation of chemo-sensitive genes and the consistent downregulation of chemo-resistant genes. Therefore, in our study, it is merely a reflective signature of the underlying mechanisms of chemo-response, for which the robustness has been validated in many cohorts. To fully understand their role in chemotherapy, functional studies are still required.
What the sources say
- Partly supportedcites [36] Christie EL Bowtell DDL Acquired chemotherapy resistance in ovarian cancer Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol. 2017 28 viii13 viii15 10.1093/annonc/mdx446 29232469 sourceExperimental — accuracy not yet measured
The Introduction says chemotherapy resistance emerges in a majority of women with high-grade serous ovarian cancer who are not primarily resistant, and the Acquired chemotherapy resistance section discusses resistance to platinum-based chemotherapy. The claim extends this to ovarian cancer patients generally and specifies that resistance develops after multiple chemotherapy cycles; our copy does not establish that timing. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Increasing evidence suggests that tumors with HR deficiency are more likely to be highly sensitive to platinum-based chemotherapy20–22.”
§ Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy > Discussion By combining gene expression profiles and chemotherapeutic response information from multiple patients and cell line datasets, the present study developed a gene expression signature comprising 16 chemotherapy-responsive genes, which could predict individual responses to platinum-based chemotherapy for patients with OvCa. Although platinum-based adjuvant chemotherapy is the first-line treatment and is associated with high response rates in OvCa patients, ~30% of patients have been found to develop chemoresistance following multiple cycles of chemotherapy, and ~50% of patients with CR relapse within a few years4,18. Therefore, identifying predictive markers of response to platinum-based chemotherapy is an ongoing focus of research despite continuous efforts have been made during the past number of years. A recent review revealed that the gene signatures identified by previous studies are very dissimilar, and the vast majority of genes were identified using only one study18. In contrast to previous studies, where informative genes were identified based solely on a single dataset and did not take into consideration the heterogeneity of patient cohorts, the present study integrated multiple patient and cell line datasets with chemotherapy treatment to identify the most commonly differentially expressed genes, which were demonstrated as reliable chemotherapy-responsive genes. These chemotherapy-responsive genes include genes involved in the repair of DNA damage (MUTYH, NBR1, NEK7, NET1, and RAD17), and genes previously reported to be associated with the response to chemotherapy (FZD4, SRPK1 and UCP2)30–32. To accelerate the clinical application of our findings, the 16 reliable chemotherapy-responsive genes were integrated to form a gene expression signature (denoted IndividCRS) by comparing expression differences between chemotherapy-sensitive and chemotherapy-resistant genes. Unlike previous linear scoring models, this signature design allowed IndividCRS to have a natural cutoff (IndividCRS = 0) that divided sensitive and resistant tumors. This was associated with statistical significance and eliminated the need for the pre-collection of samples for data normalization and the establishment of trained risk score thresholds. Moreover, the predictive value of the IndividCRS was validated in multiple independent OvCa datasets derived from different laboratories that used different platforms. This demonstrated that the IndividCRS is a robust tool that may allow for the individualized and single-sample prediction of response to platinum-based chemotherapy before initiation of first-line therapy in clinical practice. Increasing evidence suggests that tumors with HR deficiency are more likely to be highly sensitive to platinum-based chemotherapy20–22. Detection of HR deficiency is a widely accepted strategy to identify platinum-sensitive tumors. However, it is worth noting that not all HRD tumors, including BRCA1/2-mutated tumors, are sensitive to platinum agents. Therefore, the relationship between HR deficiency and IndividCRS was examined in the current study, and a potential association between HR deficiency and IndividCRS was identified, indicating that the IndividCRS may be used as an indicator of HR deficiency which need be further investigated using functional experiments. In addition, the IndividCRS can further discriminate between chemoresistance and chemosensitivity in HR-deficient tumors, which may provide valuable information for guiding HRD-targeted clinical trials. Conflicting results have been reported regarding the outcome of OvCa patients harboring BRCA1/2 mutations. A number of studies have demonstrated that not all OvCa patients harboring BRCA1/2 mutations have significantly more favorable outcome than patients with wild-type BRCA, and some patients may even develop platinum resistance33–35. By applying the IndividCRS to BRCA-deficient patients in the present study, a significant difference in OS between BRCA-deficient patients with high IndividCRS and those with low IndividCRS was observed, suggesting that BRCA-deficient patients could be further discriminated by the IndividCRS. Therefore, the IndividCRS may have important clinical applications in identifying BRCA-deficient patients with unfavorable outcomes and allow redirection to more appropriate therapies in time. Despite previous studies claiming that the existing signatures are able to predict survival or response to initial chemotherapy in OvCa patients, the majority of OvCa patients that initially respond to chemotherapy treatment develop the recurrent disease due to acquired resistance to platinum-based chemotherapy after undergoing multiple cycles of chemotherapy36. Therefore, the present study examined the relationship between changes in chemotherapy resistance and the IndividCRS during and after drug treatment. The results demonstrated that the IndividCRS reflected the dynamics of resistance during the treatment. Furthermore, the IndividCRS comprised a minimal number of reliable chemotherapy-responsive genes; the expression of which could be measured using real time-polymerase chain reaction (RT-PCR) in samples obtained by fine needle aspiration. This provides a potential avenue to monitor resistance to platinum-based chemotherapy in real-time for OvCa patients that respond to initial platinum-based chemotherapy in clinical practice, and redirect patients with chemoresistance to more appropriate therapies in time and avoid unnecessary chemotherapy treatment. Accumulating evidence suggests that an interplay exists between EMT and chemotherapeutic response in OvCa. However, previous studies investigating the role of EMT in chemoresistance report inconsistent results24. For instance, the activation of EMT by the EMT-related signaling pathways, such as endothelin A receptor, p53-mediated apoptosis, epidermal growth factor receptor/signal transducer and activator of transcription 3, transforming growth factor-β and Notch3/ERK signaling pathways37–39 or microRNAs, such as microRNA-181a and miR-200 family40,41, have been found to be associated with enhanced resistance to platinum-based chemotherapy. By contrast, several studies have indicated that patients or cell lines with mesenchymal phenotypes demonstrated higher sensitivity to cisplatin when compared with the epithelial phenotype25,42,43. Therefore, the association between EMT and the chemotherapeutic response was investigated in the current study by constructing an EMT score. The results demonstrated that the EMT score, or the key components of EMT, were all negatively correlated with the IndividCRS across multiple datasets. These results provided further evidence to support the association between EMT and platinum-based chemoresistance. In conclusion, the present study used an integrated approach involving both OvCa tumors and cell lines, to identify a number of genes that were differentially expressed between platinum-based chemotherapy-resistant samples and sensitive samples. These genes were then used to construct an individualized scoring model consisting of a 16-gene chemotherapy-responsive panel (IndividCRS) for the prediction of response to platinum-based chemotherapy. The ability of the IndividCRS to predict response to platinum-based chemotherapy and outcome was verified in multiple independent datasets deposited by different laboratories with different platform technologies. The universality and simplicity of the IndividCRS make it a promising individualized predictive tool to monitor patient resistance in a timely manner before and after platinum-based chemotherapy treatment, and can be analyzed using RT-PCR in a clinical setting. However, it is should be noted that the IndividCRS was designed to rely on the consistent upregulation of chemo-sensitive genes and the consistent downregulation of chemo-resistant genes. Therefore, in our study, it is merely a reflective signature of the underlying mechanisms of chemo-response, for which the robustness has been validated in many cohorts. To fully understand their role in chemotherapy, functional studies are still required.
What the sources say
- Supportedcites [20] Konstantinopoulos PA Ceccaldi R Shapiro GI D’Andrea AD Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer Cancer Disco. 2015 5 1137 1154 10.1158/2159-8290.CD-15-0714 PMC4631624 26463832 source
The Conventional chemotherapy section says platinum analogues are highly lethal to tumors with defective HR and reports higher response rates after platinum-based chemotherapy in patients with BRCA1/2-mutated tumors. It also describes a high correlation between HR deficiency and platinum response, supporting the citing sentence’s hedged claim. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [21] Lu J Wu D Li C Zhou M Hao D Correlation between gene expression and mutator phenotype predicts homologous recombination deficiency and outcome in ovarian cancer J. Mol. Med (Berl.) 2014 92 1159 1168 10.1007/s00109-014-1191-9 25062964 source
- Not checked — no full text of the sourcecites [22] Ledermann JA Drew Y Kristeleit RS Homologous recombination deficiency and ovarian cancer Eur. J. cancer 2016 60 49 58 10.1016/j.ejca.2016.03.005 27065456 source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Unfortunately, none of these existing gene signatures have been widely adopted in clinical practice, which may be due, in part, to the use of only one dataset for discovery that does not account for biological heterogeneity, technical biases across different datasets, the large number of genes in a signature or impractical linear scoring modeling methods17,18.”
§ Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy > Introduction
What the sources say
- Not checked — no full text of the sourcecites [17] Li B Cui Y Diehn M Li R Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer JAMA Oncol. 2017 3 1529 1537 10.1001/jamaoncol.2017.1609 28687838 PMC5710196 source
- Supportedcites [18] Lloyd KL Cree IA Savage RS Prediction of resistance to chemotherapy in ovarian cancer: a systematic review BMC Cancer 2015 15 117 10.1186/s12885-015-1101-8 25886033 PMC4371880 source
The Conclusions in our indexed copy (page not provided) state that no clinically applicable gene signature for predicting chemotherapy response in ovarian cancer had yet been identified. The Discussion also describes limitations of the reviewed signatures. Together, these support the claim that those signatures had not been widely adopted in clinical practice. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A significantly higher IndividCRS in HR-defective tumors, when compared with HR-intact tumors, was observed (Fig. 3a).”
§ Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy > Results > Correlation between the IndividCRS and HRD Recent studies indicate that the enhanced sensitivity of OvCa patients to platinum-based chemotherapy could largely be explained by HRD20–22. In the present study, the TCGA dataset (n = 557), that included patients treated with platinum-based chemotherapy, also provided DNA sequencing and methylation data. In this dataset, we identified 200 patients with BRCA mutations, BRCA methylation, defects of PTEN, defects of FA (Fanconi anemia) genes, Ras-related associated with diabetes (RAD) genes, and ATM (ataxia telangiectasia) genes (i.e., ATM, ataxia telangiectasia and Rad3-related (ATR), and CHEK1/2), as well as the amplification of EMSY as HR-defective tumors21. To investigate the relationship between the IndividCRS and HR deficiency, the distribution of IndividCRS between HR-defective tumors and HR-intact tumors was examined. A significantly higher IndividCRS in HR-defective tumors, when compared with HR-intact tumors, was observed (Fig. 3a). A total of 557 OvCa patients from the TCGA dataset were then divided into the following three groups: The HR-intact group, the high IndividCRS HR-defective group and the low IndividCRS HR-defective group. Pairwise comparisons of OS between the groups were performed and the results demonstrated that the high IndividCRS HR-defective group had a significantly better OS rate when compared with patients in the HR-intact group (log-rank test, P = 0.02; Fig. 3b). However, no significant difference in OS between the HR-intact group and the low IndividCRS HR-defective group was observed (log-rank test, P = 0.60; Fig. 3b). These results suggested that the IndividCRS are not only correlated with HRD, but can also identify a subset of HR-defective tumors with resistance to platinum-based chemotherapy. The association between BRCA1/2-deficient tumors and OS in OvCa was then analyzed using the IndividCRS. The results shown in Fig. 3c demonstrated that BRCA-deficient patients with high IndividCRS exhibit significantly better survival rates when compared with BRCA1/2-intact cases (log-rank test, P < 0.001). By contrast, BRCA-deficient patients with low IndividCRS demonstrated no significant difference in OS when compared with BRCA1/2-intact cases (log-rank test, P = 0.20; Fig. 3c). This implied that the IndividCRS could discriminate BRCA1/2-deficient tumors with various survival outcomes and distinct responses to platinum-based chemotherapy.
plainstates an associationn = 557- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in Fig. 2a, significantly higher IndividCRS were observed for sensitive cell lines when compared with resistant cell lines (unpaired t-test, P = 0.041).”
§ Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy > Results > Validation of the IndividCRS in independent cell lines and patient samples
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
38 more claims
Create a free account to see all 73 claims and to verify the 7 references still open.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given its widespread use, it comes as no surprise that prior work has assessed the utility of mutational and transcriptomic signatures in predicting response to this drug; yet, to the best knowledge of these authors, none of these advancements have been translated into routine clinical care15–19.”
From Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature (2023) · cites this paper as [19]
Experimental — accuracy not yet measured
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Ovarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Tan, T. Z., Miow, Q. H., Miki, Y., Noda, T., Mori, S., Huang, R. Y., & Thiery, J. P. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404208 · Cited by 792
Kurrey, N. K., Jalgaonkar, S. P., Joglekar, A. V., Ghanate, A. D., Chaskar, P. D., Doiphode, R. Y., & Bapat, S. A. (2009) · Stem Cells · doi:10.1002/stem.154 · Cited by 655
ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
Zhang, P., Sun, Y., & Ma, L. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1006048 · Cited by 611
Yang, D., Khan, S., Sun, Y., Hess, K., Shmulevich, I., Sood, A. K., & Zhang, W. (2011) · JAMA · doi:10.1001/jama.2011.1456 · Cited by 599
Cited by
Noncoding RNAs in gastric cancer: implications for drug resistance
Wei, L., Sun, J., Zhang, N., Zheng, Y., Wang, X., Lv, L., Liu, J., Xu, Y., Shen, Y., & Yang, M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01185-7 · Cited by 468
Self-citationYou, B., Freyer, G., González-Martín, A., Lheureux, S., McNeish, I. A., Penson, R. T., Pignata, S., & Pujade-Lauraine, É. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102294 · Cited by 59
Sun, J., Yan, C., Xu, D., Zhang, Z., Li, K., Li, X., Zhou, M., & Hao, D. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01692-4 · Cited by 57
“Tumour samples with BRCA1/2 mutation, BRCA1 hypermethylation, EMSY amplification, defects of PTEN, RAD, FA, ATR, ATM, CHEK1/2 or PALB2 were considered as homologous recombination (HR)-defective tumours according to previous studies [14, 19, 20].”
MethodSelf-citationComparative analysis of syngeneic mouse models of high-grade serous ovarian cancer
Cook, D. P., Galpin, K. J. C., Rodriguez, G. M., Shakfa, N., Wilson‐Sanchez, J., Echaibi, M., Pereira, M., Matuszewska, K., Haagsma, J., Murshed, H., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05529-z · Cited by 41
Zhao, H., Gu, S., Bao, S., Yan, C., Zhang, Z., Hou, P. K., Zhou, M., & Sun, J. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa069 · Cited by 30
Self-citation
Metadata
- Authors
- Sun, J., Bao, S., Xu, D., Zhang, Y., Su, J., Liu, J., Hao, D., & Zhou, M.
- Affiliations
- Wenzhou Medical University (CN)
- Harbin University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University of Macau (MO)
- Corresponding author
- Hao, Dapeng
- Zhou, Meng
- Venue
- Cell Death & Disease
- Published
- 2019-09-10
- Volume
- 10
- Issue
- 9
- Pages
- 661-661
- ISSN
- 2041-4889 (ISSN-L)
- PMC
- PMC6737147
- OpenAlex
- W2972563948
- Semantic Scholar
- 8bcef6f017313639826e737725410ad753b4693f
- Cited by
- 23
- References
- 46
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 8
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cell Death and Disease (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Wenzhou Medical University (QTJ18023, QTJ18029, QTJ18024)
- National Natural Science Foundation of China (31701153)
- Wenzhou Institute of Biomaterials and Engineering
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- ovarian cancer, platinum-based chemotherapy, chemotherapy response prediction, gene expression signatures, tumor heterogeneity, homologous recombination deficiency, personalized chemotherapy, acquired drug resistance, prognostic factors
- MeSH terms
- Female, Humans, Ovarian Neoplasms, Platinum, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Databases, Nucleic Acid, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy. https://app.cochat.ai/papers/10.1038/s41419-019-1874-9
- The paper
- Sun, J., Bao, S., Xu, D., Zhang, Y., Su, J., Liu, J., Hao, D., & Zhou, M. (2019). Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy. Cell Death & Disease. https://doi.org/10.1038/s41419-019-1874-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.